Apyx Medical Corporation (APYX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.60 (-3.35% 1D, market cap $113.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, APYX ranks #778 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $113.5M) and SKYA (SkyAI Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).
Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 49.1 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While APYX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.77) and Max Pain ($2.73) forces dealer call-delta covering toward $5.33.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Apyx Medical Corporation (APYX) dropped -3.35% to $2.60, trading at 12% of its 52-week range ($2.25 – $5.08). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring
CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring Sy
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on APYX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for APYX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Apyx Medical Corporation (APYX) ranks #778 by composite RQD confidence (32/100, grade E) and #644 by equity capitalization ($113.3M). Within this direct 5-issuer industry benchmark cohort, APYX leads on earnings valuation at N/A trailing P/E, while APYX leads on capital efficiency and profitability with -28.9% ROIC and 62.5% gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with APYX at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| APYX
ACTIVE
Apyx Medical Corporation | E | 32/100 | — | 62.5% | -28.9% | -3.35% | $113.3M | Benchmark Subject |
| PYPD PolyPid Ltd. | D | 44/100 | — | — | -35.0% | -3.58% | $113.5M | /pypd-vs-apyx → |
| SKYA SkyAI Inc. | D- | 42/100 | — | -30.0% | -35.0% | +1.37% | $126.7M | /skya-vs-apyx → |
| LUNG Pulmonx Corporation | D- | 39/100 | — | 74.2% | -35.0% | -5.05% | $135.9M | /lung-vs-apyx → |
| NYXH Nyxoah SA | D | 45/100 | — | — | — | -1.85% | $88.9M | /nyxh-vs-apyx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apyx Medical Corporation (APYX) reported GAAP revenue of $52.8M (+9.9% vs. FY2024 revenue of $48.1M , and +0.9% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of -$8.0M, and free cash flow of -$9.1M (+51.4% YoY). On the balance sheet, APYX closed FY2025 with $66.8M in total assets against $34.8M in total debt (Altman Z-Score: 0.75, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $52.8M | -$11.2M | -$8.0M | -$9.1M | $66.8M | $34.8M |
| FY2024 (FY) | 2024-12-31 | $48.1M | -$23.5M | -$18.0M | -$18.8M | $64.8M | $33.9M |
| FY2023 (FY) | 2023-12-31 | $52.3M | -$18.7M | -$5.2M | -$5.2M | — | — |
As of 2026-11-02, Apyx Medical Corporation (NASDAQ: APYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.60 (-3.35% 1D, market cap $113.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, APYX ranks #778 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), APYX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 62.5%, and ROIC of -28.9%. By comparison, PYPD (PolyPid Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $113.5M) and SKYA (SkyAI Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, APYX leads on earnings multiple (N/A) while APYX leads on capital efficiency (-28.9% ROIC).
Per APYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000719135), Apyx Medical Corporation generated $52.8M in revenue (+9.9% YoY), -$11.2M in net income, and -$9.1M in free cash flow against $66.8M in total assets and $34.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
APYX last traded at $2.60 (-3.35% on volume of 38,095 shares), positioning the stock -6.14% below its 50-day simple moving average ($2.77) and -27.78% below its 200-day simple moving average ($3.60). Across its 52-week range of $2.25 to $5.08, APYX sits at the 12.4% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.27 to $2.93).
Why APYX Stock dropped -3.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).